Are you looking for out-license opportunities and commercialization partners with good resources and capital? An increasing number of Chinese pharma companies are looking for assets for the Chinese market!
We have hand-picked these top Chinese pharma companies who are attending the China Focus@Europe Spring. Here are some highlights of these companies. Register now and connect with Chinese pharma and investor in biotech innovation!
Check the Event Website for more participating Chinese companies and our previous events.
| Register Now! |
Jiangsu Hengrui Medicine: a leading biopharmaceutical company based in China with annual sales of $2.2 billion in 2017, established in 1970. Hengrui is devoted to empowering healthier lives through research, with a team of over 20,000 employees in China, the United States, Australia, Japan and Germany. Hengrui currently has 4 China NMPA approved new molecular entities, as well as over 35 new molecular entities in clinical development in China, the United States, and Australia, across oncology, anesthesiology and pain management, immunology & inflammation, and cardiovascular and metabolic diseases.
Qilu Pharmaceutical: One of the leading pharmaceutical companies in China, focusing on the development, manufacturing and marketing of innovative and generic drugs in various therapeutic areas such as Oncology, Cerebrovascular & Cardiovascular, Anti-infections, Psychological & Neurological Systems, Respiratory System, and Ophthalmological Diseases. Qilu is committed to build world class R&D teams around the globe and has established innovative drug discovery centers in Boston, Seattle, San Francisco, and Shanghai. Qilu has built state of art manufacturing facilities, which have been approved by USFDA, EMA, MHRA, PMDA of Japan, and other regulatory authorities. Qilu has assembled top sales and marketing teams which ranked number one in China for the past ten years. Qilu aims to establish extensive cooperation with domestic and international partners to bring innovative drugs to the China market and help the wellbeing of Chinese patients.
Fosun Pharma: As a Shanghai and Hong Kong Stock Exchange Dual (A+H) listed company, Fosun is China’s No.1 pharmaceutical & healthcare distributor, the No. 6 of domestic sales revenue of prescription drugs for hospitals, with sales revenue of more than 100 million RMB, and with 75 IND approvals since 2015, including 5 IND approvals by US FDA.
BuChang Pharma: Established in 1993 and listed in Shanghai Stock Exchange in 2016 (SH 603858), with 15 pharmaceutical factories, more than 180 pipelines in different stages, and more than 2,000 sale rep. offices. Buchang specializes in the R&D, production and sale of TCM patent medicines, supplemented by many fields, i.e., hi-tech industry and health industry. The Company has set up its production bases in Shandong, Shaanxi, Hebei and the Northeast China, with its marketing network spreading all over major provinces of China.
Chia Tai Tianqing Pharmaceutical Group: Founded in 1969, headquartered in Lianyungang and Nanjing, Jiangsu province, Chia Tai Tianqing (CTTQ) is a leading pharmaceutical company with integrated R & D, manufacturing, distribution, marketing, and sales in China. Its holding company Sino Biopharmaceutical Limited has been listed in Hong Kong stock market (HK 1177) since 2003. CTTQ is the market leader in drugs treating liver diseases in China since mid-1990s. With marketed drugs for the treatment of liver disease, cancer, cardiovascular, respiratory and infectious disease, etc., CTTQ generated sales revenue of 2.7 billion USD in 2017.